Sanofi India Q2 FY26: PAT rises 20%, margins improve to 27%
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanofi India Q2 FY26 revenue grew 7.7% YoY to Rs 437.7 crore. PAT rose 20.1% to Rs 83.5 crore; EPS at Rs 36.26 vs Rs 30.18. PBT up 19% to Rs 112 crore; PBT margin improved to 27% from 24% on lower operating costs. Diabetes portfolio grew 14% with 58% value share. H1 revenue dipped 3.4% to Rs 910 crore. CFO Rachid Ayari to step down effective Sept 30, 2026.
Margin expansion and profit growth signal operational discipline; diabetes franchise strength supports outlook despite modest top-line and CFO transition.